Last updated: November 5, 2026
UCB Inc. v. Zydus Worldwide DMCC, No. 1:16-cv-01023-RGA, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Zydus’s abbreviated new drug application for generic lacosamide, marketed by UCB as Vimpat. The case concerned UCB’s patent rights covering lacosamide, an antiseizure drug used for partial-onset seizures.
The litigation ended without a reported trial judgment or Federal Circuit merits decision. The docket reflects resolution through dismissal, consistent with a confidential settlement or other negotiated disposition. The case did not produce a public finding that the asserted UCB patent claims were invalid or not infringed.
What drug was at issue in UCB v. Zydus?
The case involved lacosamide, the active ingredient in Vimpat.
| Item |
Details |
| Brand drug |
Vimpat |
| Active ingredient |
Lacosamide |
| Patent holder and plaintiff |
UCB Inc. and related UCB entities |
| Generic applicant |
Zydus Worldwide DMCC and affiliated Zydus entities |
| Regulatory pathway |
ANDA under the Hatch-Waxman Act |
| Court |
U.S. District Court for the District of Delaware |
| Case number |
1:16-cv-01023-RGA |
| Judge |
Richard G. Andrews |
| Filing period |
2016 |
| Case type |
Paragraph IV patent litigation |
| Outcome |
Dismissed without a reported merits judgment |
Lacosamide is a small-molecule product. Zydus therefore challenged UCB’s patent rights through the ANDA and Paragraph IV certification process rather than through the biosimilar pathway under the Biologics Price Competition and Innovation Act.
What patents protected Vimpat in the Zydus litigation?
The principal patent associated with the lacosamide Paragraph IV litigation was U.S. Patent No. 7,691,001, which covered lacosamide-related subject matter and was listed for Vimpat.
| Patent |
Subject matter |
Relevance |
| U.S. Patent No. 7,691,001 |
Lacosamide compound and related pharmaceutical claims |
Principal patent in the lacosamide ANDA litigation |
| Other Vimpat-listed patents |
Product, formulation, or method-of-use rights depending on listing period |
Potentially relevant to other defendants and dosage forms |
The ’001 patent was also litigated against other generic applicants. In UCB, Inc. v. Accord Healthcare, Inc., the Federal Circuit reviewed the validity of the patent after a Delaware district court decision. The Federal Circuit affirmed the district court’s determination that the asserted claims were not invalid for obviousness. That decision strengthened UCB’s position in the broader lacosamide patent campaign, although it was not a merits ruling in the Zydus case. [1]
The precise claims asserted against Zydus must be determined from the complaint, claim charts, and subsequent docket filings. The public case record is best understood as part of UCB’s broader effort to enforce the ’001 patent against ANDA applicants.
What was Zydus’s Paragraph IV challenge?
Zydus’s ANDA included a Paragraph IV certification directed at UCB’s listed lacosamide patent rights. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.
The certification gave UCB a statutory basis to file suit under 35 U.S.C. § 271(e)(2). The filing of the infringement action triggered the Hatch-Waxman 30-month stay, subject to statutory exceptions or an earlier court order.
The likely legal issues were:
- Whether Zydus’s proposed lacosamide product would infringe the asserted claims.
- Whether the asserted claims were invalid for obviousness or other statutory grounds.
- Whether claim scope covered the proposed generic dosage forms.
- Whether UCB could obtain an injunction preventing FDA approval or commercial launch before patent expiration.
The case was not a conventional commercial patent dispute involving an already marketed competing product. It was an artificial infringement action created by the ANDA filing.
How did the court resolve the UCB-Zydus litigation?
The case ended through dismissal rather than a reported decision following trial.
No published opinion in the case establishes that:
- UCB’s asserted claims were invalid;
- Zydus’s product was non-infringing;
- Zydus received an immediate right to launch;
- UCB obtained a permanent injunction; or
- the court awarded damages.
The dismissal indicates that the parties resolved the dispute privately or otherwise agreed to terminate the action. Hatch-Waxman settlements commonly include a negotiated generic entry date, but the commercial terms of this case were not publicly disclosed in the reported docket materials.
A dismissal should not be treated as a ruling on patent validity. It preserved uncertainty regarding the merits of the UCB claims against Zydus while avoiding the litigation risk associated with trial and appeal.
Was there a public settlement agreement?
The case’s termination is consistent with a settlement-related dismissal, but the publicly available record does not establish the economic terms of any agreement.
The key settlement terms that would affect market analysis include:
- Zydus’s agreed launch date;
- whether launch was authorized before the ’001 patent’s expiration;
- whether Zydus received a license;
- whether the agreement included supply, royalty, or business restrictions;
- whether UCB retained rights against other Zydus dosage forms; and
- whether Zydus preserved or waived any 180-day generic exclusivity position.
Without those terms, the case cannot be used to establish the exact date of Zydus’s authorized market entry.
The Federal Trade Commission has treated certain Hatch-Waxman settlement provisions as potentially relevant to competition analysis, particularly where a brand company provides value to a generic applicant in exchange for delayed entry. No public finding in this case establishes that the UCB-Zydus resolution constituted an unlawful reverse-payment settlement. [2]
What was the Orange Book status of Vimpat?
Vimpat was approved by the FDA in 2008 for partial-onset seizures. The product’s Orange Book-listed patent protection extended beyond the basic regulatory exclusivity period.
| Regulatory event |
Date or status |
| Initial U.S. approval |
2008 |
| Regulatory pathway |
New drug application |
| Active ingredient |
Lacosamide |
| Regulatory exclusivity |
Expired before the principal patent barrier |
| Principal patent barrier |
U.S. Patent No. 7,691,001 |
| Approximate patent expiration |
2022, subject to any applicable statutory extensions |
| Generic pathway |
ANDA with Paragraph IV certification |
The relevant distinction is between FDA exclusivity and patent protection. Vimpat’s commercial protection after the initial approval period depended primarily on patent rights, not on new chemical entity exclusivity.
The Orange Book lists patents and associated information supplied by the NDA holder. It does not decide whether a listed patent is valid or infringed. Those issues are determined through litigation or settlement.
When did lacosamide lose exclusivity?
The principal U.S. patent barrier for lacosamide expired in 2022, based on the ordinary term of the ’001 patent and subject to any applicable patent-term adjustment or pediatric extension.
Generic lacosamide products began entering the U.S. market around the 2022 patent-expiration period. The timing varied by applicant, dosage form, FDA approval status, litigation settlement, and any applicable 180-day exclusivity period.
The loss of the ’001 patent barrier materially reduced UCB’s ability to block standard lacosamide tablets and oral-solution products. It did not eliminate every possible patent issue. Separate rights could still affect specific formulations, manufacturing processes, or methods of treatment if those rights remained valid and listed or enforceable.
Did the case involve biosimilar risk?
No. Lacosamide is a small-molecule active ingredient, and Zydus pursued an ANDA. The case did not involve a biologic, biosimilar interchangeability, or the BPCIA patent-exchange process.
The relevant competitive risks were:
- generic tablets;
- generic oral solution;
- potential dosage-form competition;
- pharmacy substitution;
- price erosion after generic approval; and
- loss of branded market share after patent expiry.
This distinction matters because biosimilar litigation usually involves a different statutory framework, more complex product-specific patent portfolios, and different substitution dynamics.
How strong was UCB’s patent estate?
UCB’s position was materially stronger after the Federal Circuit’s decision in the related Accord litigation. The Federal Circuit upheld the relevant patent claims against the asserted obviousness challenge, confirming that the patent was not easily defeated on the existing trial record. [1]
The estate nevertheless had structural limitations:
| Strength |
Limitation |
| Federal Circuit validity precedent supported the ’001 patent |
Patent term ended in 2022 |
| Core compound protection could block ordinary generic lacosamide products |
A finite patent term permitted eventual generic entry |
| ANDA litigation delayed approval during the statutory stay |
Settlement could accelerate entry relative to full patent-term enforcement |
| Multiple defendants could be sued under Hatch-Waxman |
Parallel litigation increased cost and inconsistent-outcome risk |
The strongest protection was the core patent covering lacosamide-related subject matter. Formulation and method-of-use claims generally provide narrower protection because they may cover only specific dosage forms, dosing regimens, or indications.
What generic launch risks did Zydus present?
Zydus presented the standard commercial threat associated with an ANDA applicant challenging a branded small-molecule product.
Early launch risk
If Zydus prevailed on invalidity or non-infringement, it could have launched before expiration of the asserted patent. That would have created immediate price competition and reduced UCB’s exclusivity period.
Settlement-authorized launch risk
If the parties settled, Zydus could have received a contractually defined launch date. Such a date might have preceded the patent’s nominal expiration, depending on the settlement terms.
Post-expiration launch risk
After expiration of the principal patent barrier, Zydus could launch if FDA approval and other regulatory conditions were satisfied. At that point, the principal risk shifted from legal uncertainty to pricing, substitution, supply capacity, and contracting.
Dosage-form risk
The commercial effect depended on the ANDA dosage form. Generic tablets generally create faster substitution pressure than oral solutions, while different strengths and presentations can affect the speed of pharmacy and payer adoption.
What was the commercial exposure for UCB?
Vimpat generated substantial revenue for UCB before generic competition. UCB reported Vimpat net sales of approximately EUR 1.5 billion in 2021, before the full impact of U.S. generic erosion. [3]
The commercial exposure included:
- direct U.S. revenue loss after generic entry;
- price reductions from pharmacy substitution;
- payer pressure on branded lacosamide;
- reduced leverage in formulary negotiations; and
- possible spillover into other UCB central nervous system products.
The UCB-Zydus case therefore had more value than the individual defendant’s potential volume. A favorable ruling could have supported enforcement against other ANDA applicants. A settlement could preserve litigation certainty while permitting controlled generic entry.
How does UCB v. Zydus compare with UCB v. Accord?
| Issue |
UCB v. Zydus |
UCB v. Accord |
| Court |
District of Delaware |
District of Delaware, with Federal Circuit appeal |
| Product |
Lacosamide/Vimpat |
Lacosamide/Vimpat |
| Principal patent |
U.S. Patent No. 7,691,001 |
U.S. Patent No. 7,691,001 |
| Public merits ruling |
No reported final merits judgment |
Federal Circuit merits decision |
| Validity outcome |
Not adjudicated publicly in the case |
Asserted claims upheld against the challenged obviousness theory |
| Resolution |
Dismissal |
Appellate judgment |
| Analytical value |
Shows Zydus-specific settlement or termination |
Provides broader precedent supporting patent validity |
The Accord decision is relevant background, not a substitute for a Zydus-specific judgment. It supports the strength of UCB’s patent position but does not disclose the terms under which Zydus exited or resolved its case.
Key Takeaways
- UCB Inc. v. Zydus Worldwide DMCC, No. 1:16-cv-01023-RGA, was a Delaware Hatch-Waxman case involving generic lacosamide.
- The litigation centered on UCB’s Vimpat patent estate, principally U.S. Patent No. 7,691,001.
- Zydus challenged UCB’s patent through a Paragraph IV ANDA certification.
- The case ended by dismissal without a reported trial or appellate merits ruling.
- The public record does not establish Zydus’s precise authorized launch date or settlement economics.
- The related UCB v. Accord decision upheld the asserted patent claims against an obviousness challenge and strengthened UCB’s broader litigation position.
- The principal lacosamide patent barrier expired in the 2022 period, after which generic competition expanded.
- The case involved an ANDA and generic-entry risk, not biosimilar litigation.
FAQs About UCB v. Zydus and Lacosamide Patent Litigation
Did Zydus win the UCB lacosamide patent case?
No public merits judgment establishes that Zydus won. The case ended through dismissal, and the public record does not report a ruling invalidating UCB’s patent or finding non-infringement.
What was the main patent in the UCB lacosamide litigation?
U.S. Patent No. 7,691,001 was the principal patent associated with the Vimpat lacosamide litigation, including related cases against other ANDA applicants.
Could Zydus launch generic Vimpat before 2022?
The answer depends on the private resolution terms and FDA approval status. The public dismissal record does not establish Zydus’s exact launch date or whether an agreement authorized an early launch.
Is UCB v. Zydus relevant to current generic lacosamide litigation?
Its direct blocking effect ended with termination and the expiration of the principal patent barrier. Its strategic relevance lies in UCB’s broader enforcement campaign and the contemporaneous validity precedent involving the ’001 patent.
Did the case involve UCB’s Briviact product?
No. The case is associated with lacosamide and Vimpat, not brivaracetam and Briviact.
References
-
UCB, Inc. v. Accord Healthcare, Inc., 890 F.3d 1235 (Fed. Cir. 2018).
-
Federal Trade Commission. (2013). Authorized generic drugs: Short-term effects and long-term impact. U.S. Federal Trade Commission.
-
UCB. (2022). Annual report 2021. UCB S.A.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
